Joseph A. Buckwalter

Joseph A. Buckwalter

Auto-generated profile, based on publicly available information

Joseph A. Buckwalter

Department of Orthopedics and Rehabilitation, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA

Research Focus & Metrics

Academic Career Length

55Years (1972-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2000 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
DFDavid T. Felson
David T. Felson
RLReva C. Lawrence
Reva C. Lawrence
PDPaul A. Dieppe
Paul A. Dieppe
RHRosemarie Hirsch
Rosemarie Hirsch
CHCharles G. Helmick
Charles G. Helmick
JFJames F. Fries
James F. Fries
Osteoarthritis is the most common form of arthritis, affecting millions of people in the United States. It is a complex disease whose etiology bridges biomechanics and biochemistry. Evidence is growing for the role of systemic factors (such as genetics, dietary intake, estrogen use, and bone density) and of local biomechanical factors (such as muscle weakness, obesity, and joint laxity). These risk factors are particularly important in weight-bearing joints, and modifying them may present opportunities for prevention of osteoarthritis-related pain and disability. Major advances in management to reduce pain and disability are yielding a panoply of available treatments ranging from nutriceuticals to chondrocyte transplantation, new oral anti-inflammatory medications, and health education. This article is part 1 of a two-part summary of a National Institutes of Health conference. The conference brought together experts on osteoarthritis from diverse backgrounds and provided a multidisciplinary and comprehensive summary of recent advances in the prevention of osteoarthritis onset, progression, and disability. Part 1 focuses on a new understanding of what osteoarthritis is and on risk factors that predispose to disease occurrence. It concludes with a discussion of the impact of osteoarthritis on disability.

1 November 2006 in Journal of Orthopaedic Trauma
Verified
Journal Article
Closed access
TBThomas D Brown
Thomas D Brown
RJRichard C Johnston
Richard C Johnston
CSCharles L Saltzman
Charles L Saltzman
JMJ. Lawrence Marsh
J. Lawrence Marsh
JBJoseph A Buckwalter
Joseph A Buckwalter
Although posttraumatic osteoarthritis (OA) is a common and important entity in orthopedic practice, no data presently exist regarding its prevalence or its relative burden of disease. A population-based estimate was formulated, based on one large institution's experience in terms of its fraction of patients with OA presenting to lower-extremity adult reconstructive clinics with OA of posttraumatic origin. The relative proportion of these patients undergoing total joint replacement provided a basis for extrapolating institutional experience with posttraumatic OA to a populationwide estimate because the numbers of lower-extremity total joint arthroplasty procedures performed were reliably tabulated both within the institution and populationwide. By this methodology, approximately 12% of the overall prevalence of symptomatic OA is attributable to posttraumatic OA of the hip, knee, or ankle. This corresponds to approximately 5.6 million individuals in the United States being affected by posttraumatic OA sufficiently severe to have caused them to present for care by an orthopedic lower-extremity adult reconstructive surgeon. Further, based on the relative prevalence of OA versus rheumatoid arthritis, and their relative impacts as assessed by the SF-36 (Short-Form 36) lower-extremity physical composite scores, about 85.5% of the societal costs of arthritis are attributable to OA. The corresponding aggregate financial burden specifically of posttraumatic OA is Dollars 3.06 billion annually, or approximately 0.15% of the total U.S. health care direct cost outlay.

1 October 2007 in Neuron
Verified
Journal Article
Closed access
ECEric Courchesne
Eric Courchesne
KPKaren Pierce
Karen Pierce
CSCynthia M. Schumann
Cynthia M. Schumann
ERElizabeth Redcay
Elizabeth Redcay
JBJoseph A. Buckwalter
Joseph A. Buckwalter
JMJohn Morgan
John Morgan

1 August 2010 in Biological Psychiatry
Verified
Journal Article
Closed access
JMJohn T. Morgan
John T. Morgan
GCGursharan Chana
Gursharan Chana
CPCarlos A. Pardo
Carlos A. Pardo
CACristian Achim
Cristian Achim
KSKaterina Semendeferi
Katerina Semendeferi
IEIan P. Everall
Ian P. Everall

11 February 2011 in Journal of Orthopaedic Research
Verified
Journal Article
Open access
PDF file
DADonald D. Anderson
Donald D. Anderson
SCSusan Chubinskaya
Susan Chubinskaya
Farshid GuilakFarshid Guilak
Farshid Guilak
JMJames A. Martin
James A. Martin
TOTheodore R. Oegema
Theodore R. Oegema
JBJoseph A. Buckwalter
Joseph A. Buckwalter
Even with current treatments of acute joint injuries, more than 40% of people who suffer significant ligament or meniscus tears, or articular surface injuries, will develop osteoarthritis (OA). Correspondingly, 12% or more of all patients with lower extremity OA have a history of joint injury. Recent research suggests that acute joint damage that occurs at the time of an injury initiates a sequence of events that can lead to progressive articular surface damage. New molecular interventions, combined with evolving surgical methods, aim to minimize or prevent progressive tissue damage triggered by joint injury. Seizing the potential for progress in the treatment of joint injuries to forestall OA will depend on advances in (1) quantitative methods of assessing the injury severity, including both structural damage and biologic responses, (2) understanding of the pathogenesis of post‐traumatic OA, taking into account potential interactions among the different tissues and the role of post‐traumatic incongruity and instability, and (3) application of engineering and molecular research to develop new methods of treating injured joints. This paper highlights recent advances in understanding of the structural damage and the acute biological response following joint injury, and it identifies important directions for future research. © 2011 Orthopaedic Research Society Published by Wiley Periodicals, Inc. J Orthop Res 29:802–809

1 October 2004 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
JBJoseph A Buckwalter
Joseph A Buckwalter
CSCharles Saltzman
Charles Saltzman
TBThomas Brown
Thomas Brown
Osteoarthritis, the clinical syndrome of joint pain and dysfunction caused by joint degeneration, affects more people than any other joint disease. There are no consistently effective methods for preventing osteoarthritis or slowing its progression, and symptomatic treatments provide limited benefit for many patients. Osteoarthritis disables about 10% of people who are older than 60 years, compromises the quality of life of more than 20 million Americans, and costs the United States economy more than $60 billion per year. The incidence of osteoarthritis rises precipitously with age; as a result, the prevalence and burden of this disorder is increasing rapidly. Study of the patterns osteoarthritis incidence and prevalence shows that it occurs frequently in the hand, foot, knee, spine and hip, but rarely in the ankle, wrist, elbow, and shoulder, and the most important universal risk factors are age, excessive joint loading, and joint injury. Analysis of the impact of osteoarthritis raises questions that include: Why does the incidence increase progressively with age? Why are some joints rarely affected? How do mechanical forces cause joint degeneration? What biologic and mechanical factors slow or accelerate the rate of joint degeneration? Answering these questions could lead to effective methods of preventing osteoarthritis and slowing its progression.